TY - JOUR
T1 - Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm
T2 - An exploratory study
AU - Jamil, Laith H.
AU - Chindris, Ana M.
AU - Gill, Kanwar R.S.
AU - Scimeca, Daniela
AU - Stauffer, John A.
AU - Heckman, Michael G.
AU - Meek, Shon E.
AU - Nguyen, Justin H.
AU - Asbun, Horacio J.
AU - Raimondo, Massimo
AU - Woodward, Timothy A.
AU - Wallace, Michael B.
PY - 2012
Y1 - 2012
N2 - Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.
AB - Background. Glycemic control following total pancreatectomy (TP) has been thought to be difficult to manage. Diffuse intraductal papillary mucinous neoplasm (IPMN) is a potentially curable precursor to pancreatic adenocarcinoma, best treated by TP. Objective. Compare glycemic control in patients undergoing TP for IPMN to patients with type 1 diabetes mellitus (DM). Design/Setting. Retrospective cohort. Outcome Measure. Hemoglobin A1C(HbA1C) at 6, 12, 18, and 24 months after TP. In the control group, baseline was defined as 6 months prior to the first HbA1c measure. Results. Mean HgbA1C at each point of interest was similar between TP and type I DM patients (6 months (7.5 versus 7.7, P = 0.52), 12 months (7.3 versus 8.0, P = 0.081), 18 months (7.7 and 7.6, P = 0.64), and at 24 months (7.3 versus 7.8, P = 0.10)). Seven TP patients (50) experienced a hypoglycemic event compared to 65 type 1 DM patients (65, P = 0.38). Limitations. Small number of TP patients, retrospective design, lack of long-termfollowup. Conclusion. This suggests that glycemic control following TP for IPMNcan be well managed, similar to type 1 DM patients. Fear of DM following TP for IPMN should not preclude surgery when TP is indicated.
UR - http://www.scopus.com/inward/record.url?scp=84866116801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866116801&partnerID=8YFLogxK
U2 - 10.1155/2012/381328
DO - 10.1155/2012/381328
M3 - Article
C2 - 22966212
AN - SCOPUS:84866116801
VL - 2012
JO - HPB Surgery
JF - HPB Surgery
SN - 0894-8569
M1 - 381328
ER -